This trial is active, not recruiting.

Condition partial epilepsy
Treatments ykp3089, placebo
Phase phase 2
Sponsor SK Life Science
Start date July 2013
End date July 2015
Trial size 437 participants
Trial identifier NCT01866111, YKP3089C017


This is a multicenter, double-blind, randomized, placebo-controlled dose response study, with an 8-week prospective baseline and an 18 week double-blind treatment period (including a 6-week titration phase and 12 week maintenance phase), followed by a 3-week blinded study drug taper period (for subjects leaving the study) or a 2-week blinded conversion period (for subjects who will participate in the open-label extension).

The primary objective of this study is to determine the effective dose range of YKP3089 as adjunctive therapy for the treatment of partial seizures.

The trial will also evaluate the safety and tolerability of YKP3089 in the partial epilepsy population.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose treatment
(Placebo Comparator)
YKP3089 Low Dose
YKP3089 Medium Dose
YKP3089 High Dose

Primary Outcomes

Percent reduction in seizure frequency (average 28-day seizure rate) of complex partial and/or secondarily generalized and/or simple partial motor seizures during the double-blind phase relative to the pretreatment baseline.
time frame: 18 weeks

Secondary Outcomes

The response to treatment, defined as a 50% or greater reduction during the double blind phase in the seizure frequency from baseline for the ITT subjects.
time frame: 18 weeks

Eligibility Criteria

Male or female participants from 18 years up to 70 years old.

Inclusion Criteria: - Weight at least 40 kg - A diagnosis of partial epilepsy according to the International League Against Epilepsy's Classification of Epileptic Seizures. Diagnosis should have been established by clinical history and an electroencephalogram (EEG) that is consistent with localization related epilepsy; normal interictal EEGs will be allowed provided that the subject meets the other diagnosis criterion (ie, clinical history) - Have uncontrolled partial seizures despite having been treated with at least 1 AED within approximately the last 2 years - During the 8-week baseline period, subjects must have at least 8 partial seizures including only simple partial seizures with motor component, complex partial seizures, or secondarily generalized seizures without a seizure-free interval of greater than 25 days any time during the 8 weeks baseline. Subjects must have at least 3 of these partial seizures during each of the two consecutive 4-week segments of the baseline period - Currently on stable antiepileptic treatment regimen. Exclusion Criteria: - A history of nonepileptic or psychogenic seizures - Presence of only nonmotor simple partial seizures or primary generalized epilepsies - Presence or previous history of Lennox-Gastaut syndrome - An active CNS infection, demyelinating disease, degenerative neurologic disease, or any CNS disease deemed to be progressive during the course of the study that may confound the interpretation of the study results - Any clinically significant psychiatric illness, psychological, or behavioral problems that, in the opinion of the Investigator, would interfere with the subject's ability to participate in the study - History of alcoholism, drug abuse, or drug addiction within the past 2 years - History of status epilepticus within 3 months of Visit 1 - A "yes" answer to Question 1 or 2 of the C-SSRS (Baseline/Screening version) Ideation Section in the past 6 months or a "yes" answer to any of the Suicidal Behavior Questions in the past 2 years - More than 1 lifetime suicide attempt - Participation in any other trials involving an investigational product or device within 30 days of screening (or longer, as required by local regulations) - A history of any previous exposure to YKP3089

Additional Information

Official title A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures, With Optional Open-Label Extension
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by SK Life Science.